Dyadic International, Inc. announced findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) project which has been published in VACCINES, a leading peer-reviewed scientific journal. The successful ZAPI program focused on the following goals to enable the delivery of targeted vaccines for humans and animals, as well as therapeutic antibodies for hospital use, rapidly following a future disease outbreak by: Identifying the best protective subunit vaccines and neutralizing antibodies against potential new zoonotic diseases or strains, such as bunyaviruses (i.e., Rift Valley fever virus and Schmallenberg virus) or coronaviruses (i.e., Middle East respiratory syndrome coronavirus or MERS Co-V). Defining optimal manufacturing technologies and processes for these vaccines and antibodies to enable high-volume production capacity. Obtaining alignment with regulatory authorities and policy makers; and Securing pre-approval of new vaccine and antibody manufacturing methodologies for future emerging zoonotic viral diseases. The peer-reviewed study demonstrates the successful use of companys patented and proprietary C1-cell protein production platform to facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge.